Moderator: SABCS Co-director C. Kent Osborne, MD, director of the Dan L Duncan Cancer Center at Baylor College of Medicine
Abstracts are appended to the bottom of each news release (WEBCASTS at the bottom):
ABSTRACT Publication Number: GS3-03 Keynote-522 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer: Pathologic complete response in key subgroups
Peter Schmid. Barts Cancer Institute, Queen Mary University of London, London, United Kingdom SLIDES
Conclusion: Results suggest that adding pembrolizumab to neoadjuvant chemotherapy is beneficial for patients with the most aggressive disease and the highest unmet need.
ABSTRACT Publication Number: GS3-04 Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Luca Gianni, Chiun-Sheng Huang, Daniel Egle, Begona Bermejo, et al. SLIDES
Conclusion: Our observations may indicate that there is no therapeutic benefit to adding atezolizumab to neoadjuvant chemotherapy compared to chemotherapy alone, or it may simply mean that any beneficial effects of the combination will be seen in the longterm.
ABSTRACT Publication Number: GS4-04 Ten year results of the international breast cancer intervention study II
Jack Cuzick, Ivana Sestak, John Forbes, Mitchell Dowsett, et al. SLIDES
Conclusion: This updated analysis of the IBIS-II trial confirms the significant reduction in breast cancer occurrence withanastrozole in the post-treatment follow-up period. These results indicate a long-term preventive benefit with anastrozole for ER-positive breast cancer in postmenopausal women.
ABSTRACT Publication Number: GS4-06 Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial
Icro Meattini, Calogero Saieva, Sara Lucidi, Monica lo Russo, et al. SLIDES
Conclusion: IBTR rate after 10 years in patients with early breast cancer who were treated with APBI using IMRT technique in 5 fractions is rare and not significantly different from patients treated with WBI. OS, BCSS, DMFS, and LRR control are also comparable. Thus, APBI should be considered a reasonable alternative for a WBI in early breast cancer patients.